Altimmune began patient enrollment in the PERFORMA Phase 3 clinical trial, according to the company. The study will evaluate the safety and efficacy of pemvidutide for metabolic dysfunction-associated steatohepatitis.
The company claims pemvidutide is a balanced 1:1 dual receptor agonist targeting glucagon and GLP-1 receptors. Pemvidutide is also being investigated for alcohol use disorder and alcohol-associated liver disease.
Market metrics show Altimmune trades with a price-to-sales ratio roughly 72.5 times its historical median and has a GF Score of 28 out of 100, reflecting limited profitability and stretched valuation.
The company remains unprofitable and cash-flow-negative, with a reported market capitalization near $554 million and an Altman Z-Score of 3.92. Recent insider purchases total approximately $325,870 over the past 12 months.
Institutional holdings data indicate three prominent investors currently hold positions while three have trimmed and one has added shares in recent quarters. These financial and ownership indicators highlight elevated market expectations tied to successful development and commercialization of pemvidutide and underline the execution risks typical of late clinical-stage biotechnology firms.
